华福证券再遭监管警示，作为主办券商未查明公众公司财务造假

Core Viewpoint - Xiamen Securities Regulatory Bureau issued a warning letter to Huafu Securities for failing to diligently verify financial fraud in the issuance recommendation of Jiangping Biological Material Technology Co., Ltd. [2][4] Group 1: Regulatory Actions - Huafu Securities, as the lead underwriter, did not fulfill its due diligence responsibilities and failed to identify false records in Jiangping Biological's issuance documents [4] - The warning letter indicates that Huafu Securities violated the "Administrative Measures for the Supervision of Non-Listed Public Companies" [4] - The regulatory body emphasized the need for Huafu Securities to enhance internal control systems and improve the quality of its professional practices [4] Group 2: Financial Misconduct Details - From 2021 to 2022, Jiangping Biological and its subsidiaries inflated revenue by 147 million yuan and 152 million yuan, accounting for 68.62% and 64.87% of the reported revenue for those years, respectively [7] - The company also inflated total profits by 59 million yuan and 57 million yuan, representing 130.43% and 119.77% of the reported profits for 2021 and 2022 [7] - Jiangping Biological's issuance documents used false financial data from 2021, leading to a fundraising attempt of 4.945 million yuan and a proposed fundraising of 100 million to 120 million yuan, which ultimately did not proceed [7][8] Group 3: Previous Penalties on Huafu Securities - This is not the first penalty for Huafu Securities in 2023; in May, it received a warning from the Shanghai Stock Exchange for insufficient due diligence in a bond issuance project [9] - Additionally, a branch of Huafu Securities was penalized in April for failing to apply for a new business license within the required timeframe after a change in management [9]